Supreme Court seeks health ministry response on petition against Ranbaxy

By: | Published: April 5, 2016 1:39 AM

The Supreme Court on Monday sought the health ministry’s response on a PIL seeking cancellation of Ranbaxy Laboratories’ licence and a CBI probe against it for allegedly supplying adulterated drugs in the country.

The Supreme Court on Monday sought the health ministry’s response on a PIL seeking cancellation of Ranbaxy Laboratories’ licence and a CBI probe against it for allegedly supplying adulterated drugs in the country.

Alleging that “Ranbaxy was fined $500 million by the US Food and Drug Administration (USFDA) for making and selling adulterated drugs”, the PIL filed by advocate M L Sharma in 2014 had also sought sealing of all its manufacturing units here, including those in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh for allegedly manufacturing and supplying substandard and adulterated drugs.

A bench headed by Justice Pinaki Chandra Ghose asked the government to respond to the allegations in two weeks after the Centre informed the court that the health secretary is examining the drug controller’s test samples of the drugs manufactured by Ranbaxy.

While agreeing to examine the allegations, the apex court had in 2014 also issued notice to Ranbaxy Laboratories and others.

However, Ranbaxy had insisted that drugs sold by it in the Indian market were safe and effective and the company complied with country’s regulations.

The petitioner also sought action against Indian drug regulator, Central Drug Standards Control Organisation (CDSCO), for permitting Ranbaxy to sell drugs in India, especially in the wake of the results of the USFDA probe against the firm.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition